Cutting-edge Advanced Vaccine Facility to Make Canada Centre of Health Innovation

Sanofi - the new 150,000-square-foot Bulk Biologics Facility, at the Connaught Campus in Toronto — The new 150,000-square-foot Bulk Biologics Facility, at the Connaught Campus in Toronto

Today, the governments of Canada and Ontario announced an investment of up to $70 million towards Sanofi Pasteur Limited's $500-million project to establish one of the most advanced vaccine manufacturing facilities in the world.

The new 150,000-square-foot Bulk Biologics Facility, at the Connaught Campus in Toronto, will be the first of its kind. The company will double the output of its life-saving vaccines by 2023 and launch the Canadian researched and developed pertussis – or whooping cough – vaccine into over 30 new international markets, protecting children and families in Canada and all over the world.

Through this project, nearly 1,250 jobs will be created or maintained.

Sanofi Pasteur is the vaccines division of Sanofi, one of the world's leading healthcare companies and vaccine manufacturers globally, and produces critical vaccines to prevent infectious diseases.

Quote

Canada has a strong legacy in the research and development of vaccines. With this investment, Sanofi is renewing our longstanding commitment to making Canada central in our effort to protect and improve human health across the globe. Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease.
David Loew, Executive Vice President and Head of Sanofi Pasteur

Quick Facts

The Bulk Biologics Facility is expected to be operational in 2023.
The Toronto-based pharmaceutical manufacturer is ranked in Canada's top 30 corporate R&D spenders for 2016.
The Greater Toronto Area is home to one of North America's largest combined life sciences sectors, with over 1,400 companies employing more than 37,000 people.
Sanofi employs more than 100,000 people globally in 100 countries. Sanofi entities in Canada employ close to 1,900 people, with almost 80 percent of employment related to vaccine business.
In 2016, Canada's pharmaceutical manufacturing industry generated $10 billion in domestic production and employed close to 30,000 people and continues to be an important driver of Canada's innovation economy.
In 2016, Sanofi invested $130 million into R&D in Canada, creating jobs, business, and opportunities across the country.